ED Coding & Reimbursement Alert - 2006 Issue 25
ONCOLOGY: Make Your Voice Heard Now To Prevent Steep Drug Cuts
Subscribe or sign in to view the full article.
Article Overview
This article is for oncology practices, medical coders, and billing staff who follow Medicare drug payment policy. It summarizes a federal review of commonly billed oncology-related drugs, explains why the findings could matter for future payment adjustments, and describes the positions of CMS and the HHS Office of Inspector General. The focus is on reimbursement policy and pricing oversight rather than clinical treatment guidance.
Why This Topic Matters
The article highlights a Medicare payment issue that could affect oncology drug reimbursement and practice revenue. It is relevant to teams that monitor federal pricing reviews, payment methodology, and the risk of future cuts tied to overpayment findings.
What You Will Learn
- How a federal survey relates to oncology drug payment policy
- Why pricing oversight can affect Medicare reimbursement
- What general issues CMS and the HHS Office of Inspector General raised in response to the survey
- Why oncology billing teams monitor potential drug payment reductions
Who Should Read This
- Oncology practices
- Medical coders
- Billing staff
- Practice managers
- Reimbursement specialists
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com